The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Survival of patients with marginal zone lymphoma: Analysis of the Surveillance, Epidemiology, and End Results database
Abstract
BACKGROUND.: Prognostic factors and outcomes in patients with marginal zone lymphoma (MZL) have been studied in small cohort studies, which may not reflect the population at large. METHODS.: Clinical characteristics and survival outcomes of adult patients with MZL who were diagnosed between 1995 and 2009 were evaluated using the Surveillance, Epidemiology, and End Results (SEER) database. The authors generated clinical prognostic models for subtypes of MZL and compared survival during the periods of 1995 through 2000, 2001 through 2004, and 2005 through 2009. RESULTS.: The prognosis was significantly better for patients with mucosa‐associated lymphoid tissue (MALT) lymphoma (5‐year relative survival rate of 88.7%; P < .0001) compared with those with the splenic MZL (SMLZ)or nodal MZL (NMZL) subtypes (5‐year relative survival rates of 79.7% and 76.5%, respectively). There was evidence of improved outcomes in patients with NMZL and MALT lymphomas between 1995 and 2009 (P < .0001), with no difference noted in patients with SMZL (P = .56). Advancing age and the presence of B symptoms had prognostic significance in all MZL subtypes. Male sex and stage of disease were significant only for the NMZL and MALT categories. Survival in patients with MALT lymphomas varied depending on the site of origin, with a worse prognosis noted in those with gastrointestinal and pulmonary locations of origin (5‐year incidence rate of lymphoma‐related death, 9.5%‐14.3%) compared with ocular, cutaneous, and endocrine sites (4.5%‐7.8%; P < .0001). CONCLUSIONS.: The survival for patients with SMZL is similar to that for those with NMZL, and unlike the NMZL and MALT subtypes, it has not improved over the past decade. The prognosis of patients with MALT lymphoma varies according to the anatomical site of origin. Cancer 2013. © 2012 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Turner, J. J., Morton, L. M., Linet, M. S., Clarke, C. A., Kadin, M. E., Vajdic, C. M., Monnereau, A., Maynadié, M., Chiu, B. C.-H., Marcos-Gragera, R., et al. (2010) · Blood · doi:10.1182/blood-2010-06-289561 · Cited by 231 · cited 1×
“0001 Median follow-up (IQR), mo 42 (17-77) 35 (15-65) 35 (14-66) 47 (20-83) .”
Cited by
Smith, A., Crouch, S., Lax, S., Li, J., Painter, D., Howell, D., Patmore, R., Jack, A., & Roman, E. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.94 · Cited by 424
The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance
Zucca, E., & Bertoni, F. (2016) · Blood · doi:10.1182/blood-2015-12-624304 · Cited by 303
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma
Noy, A., de Vos, S., Thieblemont, C., Martin, P., Flowers, C. R., Morschhauser, F., Collins, G. P., Ma, S., Coleman, M., Peles, S., et al. (2017) · Blood · doi:10.1182/blood-2016-10-747345 · Cited by 298
Al‐Hamadani, M., Habermann, T. M., Cerhan, J. R., Macon, W. R., Maurer, M. J., & Go, R. S. (2015) · American Journal of Hematology · doi:10.1002/ajh.24086 · Cited by 277
Metadata
- Authors
- Olszewski, A. J., & Castillo, J. J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2012-08-14
- Volume
- 119
- Issue
- 3
- Pages
- 629-638
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1568270436
- Cited by
- 205
- References
- 1
- FWCI
- 7.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Survival of patients with marginal zone lymphoma: Analysis of the Surveillance, Epidemiology, and End Results database. https://app.cochat.ai/papers/10.1002/cncr.27773
- The paper
- Olszewski, A. J., & Castillo, J. J. (2013). Survival of patients with marginal zone lymphoma: Analysis of the Surveillance, Epidemiology, and End Results database. Cancer. https://doi.org/10.1002/cncr.27773
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.